Life Science Investing Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update 14h
Life Science Investing Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer Annual Meeting 04 November
Life Science Investing Compass Therapeutics to Participate in Upcoming November Investor Events 03 November
